Companies Kymera Therapeutics
Kymera Therapeutics (KYMR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kymera Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers29th pct.Of 15 peer CEOs
CEO pay, last three years
- $9,670,542FY2023
- $15,433,147FY2024
- $8,545,609FY2025
CEO total pay was $8,545,609 in fiscal 2025, down from $15,433,147 in fiscal 2024.
FY2025: salary $693,000 · bonus $0 · stock awards $0 · option awards $7,318,859
Executives and directors
Jared Gollob · Chief Medical OfficerBrian Adams · General CounselBruce Jacobs · CFONello Mainolfi · CEONoah Goodman · Chief Business OfficerBruce Booth · Independent DirectorElena Ridloff · Independent DirectorFelix J. Baker · Independent DirectorGorjan Hrustanovic Ph.D · Independent DirectorJeffrey Albers · Independent DirectorJohn Maraganore · Independent DirectorLeigh Morgan · Former director (through FY2025)Pamela Esposito · Independent DirectorVictor Sandor · Independent Director
Frequently asked questions
Who was the highest-paid executive at Kymera Therapeutics in fiscal 2025?
As disclosed, Nello Mainolfi (Founder, President and Chief Executive Officer) was the highest-paid executive at Kymera Therapeutics in fiscal 2025, with total compensation of $8,545,609.
How does Kymera Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Nello Mainolfi's total compensation ranked at the 29th percentile of Kymera Therapeutics's disclosed peer group.
What is Kymera Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Kymera Therapeutics's CEO-to-median employee pay ratio was 21:1.
How did shareholders vote on Kymera Therapeutics's executive compensation?
As disclosed, 96.82% of shareholders supported Kymera Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Kymera Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Kymera Therapeutics reported total board compensation of $476,750 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nello Mainolfi | $693,000 | $0 | $0 | $7,318,859 | $519,750 | $0 | $14,000 | $8,545,609 |
| Founder, President and Chief Executive Officer | ||||||||
| Brian Adams | 145,176 | 0 | 2,273,250 | 3,555,742 | 90,616 | 0 | 6,257 | 6,071,041 |
| Chief Legal Officer | ||||||||
| Noah Goodman | 293,992 | 0 | 1,052,500 | 1,631,056 | 181,726 | 0 | 12,794 | 3,172,068 |
| Chief Business Officer | ||||||||
| Jared Gollob | 507,100 | 0 | 905,100 | 1,202,886 | 285,244 | 0 | 14,000 | 2,914,330 |
| Chief Medical Officer | ||||||||
| Bruce Jacobs | 500,000 | 0 | 905,100 | 1,202,886 | 281,250 | 0 | 14,000 | 2,903,236 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nello Mainolfi | $8,545,609 | $15,433,147 | $9,670,542 | ↓ −6,887,538 |
| Brian Adams | 6,071,041 | — | — | — |
| Noah Goodman | 3,172,068 | — | — | — |
| Jared Gollob | 2,914,330 | 5,749,693 | 3,474,154 | ↓ −2,835,363 |
| Bruce Jacobs | 2,903,236 | 7,140,817 | 4,155,156 | ↓ −4,237,581 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives to lead us successfully in a competitive environment.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Nello Mainolfi | OPTION | 2025-03-03 | — | — | 365,000 | — | $7,318,859 |
| MBA | OPTION | 2025-04-08 | — | — | 100,000 | — | 1,631,056 |
| MBA | RSU | 2025-04-08 | — | — | 50,000 | — | 1,052,500 |
| Jared Gollob | RSU | 2025-03-03 | — | — | 30,000 | — | 905,100 |
| Brian Adams | RSU | 2025-09-03 | — | — | 52,500 | — | 2,273,250 |
| Bruce Jacobs | RSU | 2025-03-03 | — | — | 30,000 | — | 905,100 |
| Jared Gollob | OPTION | 2025-03-03 | — | — | 60,000 | — | 1,202,886 |
| Bruce Jacobs | OPTION | 2025-03-03 | — | — | 60,000 | — | 1,202,886 |
| Brian Adams | OPTION | 2025-09-03 | — | — | 105,000 | — | 3,555,742 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Nello Mainolfi | $0 | $0 | $7,318,859 | 0.0% |
| MBA | 1,052,500 | 0 | 1,631,056 | 0.0% |
| Jared Gollob | 905,100 | 0 | 1,202,886 | 0.0% |
| Brian Adams | 2,273,250 | 0 | 3,555,742 | 0.0% |
| Bruce Jacobs | 905,100 | 0 | 1,202,886 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jared Gollob | RSU | 6,250 | — | $486,313 |
| Bruce Jacobs | RSU | 7,917 | — | 616,022 |
| Jared Gollob | Option | 9,375 | 32.07 | — |
| Bruce Jacobs | Option | 11,875 | 32.07 | — |
| Jared Gollob | RSU | 16,250 | — | 1,264,413 |
| Bruce Jacobs | RSU | 20,833 | — | 1,621,016 |
| Bruce Jacobs | RSU | 30,000 | — | 2,334,300 |
| Jared Gollob | RSU | 30,000 | — | 2,334,300 |
| Bruce Jacobs | RSU | 32,500 | — | 2,528,825 |
| Jared Gollob | RSU | 32,500 | — | 2,528,825 |
| Nello Mainolfi | Option | 37,500 | 32.07 | — |
| Nello Mainolfi | RSU | 44,000 | — | 3,423,640 |
| Bruce Jacobs | Option | 45,000 | 30.17 | — |
| Jared Gollob | Option | 45,000 | 30.17 | — |
| Noah Goodman | RSU | 50,000 | — | 3,890,500 |
| Brian Adams | RSU | 52,500 | — | 4,085,025 |
| Jared Gollob | Option | 60,938 | 43.5 | — |
| Bruce Jacobs | Option | 78,125 | 43.5 | — |
| Nello Mainolfi | Option | 88,000 | 30.17 | — |
| Noah Goodman | Option | 100,000 | 21.05 | — |
| Brian Adams | Option | 105,000 | 43.3 | — |
| Nello Mainolfi | Option | 220,834 | 43.5 | — |
| Nello Mainolfi | Option | 273,750 | 30.17 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bruce BoothIndependent | $70,000 | $0 | $572,996 | $0 | $0 | $642,996 |
| Jeffrey AlbersIndependent · Audit · Compensation (Chair) | 65,000 | 0 | 572,996 | 0 | 0 | 637,996 |
| Felix J. BakerIndependent · Compensation | 63,875 | 0 | 572,996 | 0 | 0 | 636,871 |
| Elena RidloffIndependent · Audit (Chair) | 60,000 | 0 | 572,996 | 0 | 0 | 632,996 |
| Pamela EspositoIndependent · Audit · Nominating and Corporate Governance (Chair) | 57,583 | 0 | 572,996 | 0 | 0 | 630,579 |
| John MaraganoreIndependent · Compensation | 47,500 | 0 | 572,996 | 0 | 0 | 620,496 |
| Gorjan Hrustanovic Ph.DIndependent | 45,000 | 0 | 572,996 | 0 | 0 | 617,996 |
| Victor SandorIndependent | 40,000 | 0 | 572,996 | 0 | 0 | 612,996 |
| Leigh MorganIndependent · Departed during FY | 27,792 | 0 | 0 | 0 | 0 | 27,792 |
| Nello MainolfiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $476,750 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $476,750 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kymera Therapeutics as a peer
Companies that benchmark against KYMR
19 companies name KYMR as a compensation peer
- ANAPTYSBIO, INCANABFY2025
- Apogee Therapeutics, Inc.APGEFY2025
- Atrium Therapeutics, Inc.RNAFY2024
- Avidity Biosciences, Inc.RNAMFY2024
- C4 Therapeutics, Inc.CCCCFY2025
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Disc Medicine, Inc.IRONFY2025
- Dyne Therapeutics, Inc.DYNFY2025
- Edgewise Therapeutics, Inc.EWTXFY2025
- IDEAYA Biosciences, Inc.IDYAFY2025
- Immunovant, Inc.IMVTFY2026
- Jade Biosciences, Inc.JBIOFY2025
- Kura Oncology, Inc.KURAFY2025
- Nurix Therapeutics, Inc.NRIXFY2025
- Oruka Therapeutics, Inc.ORKAFY2025
- Perspective Therapeutics, Inc.CATXFY2025
- PLIANT THERAPEUTICS, INC.PLRXFY2025
- Relay Therapeutics, Inc.RLAYFY2025
- Spyre Therapeutics, Inc.SYREFY2025
- Tango Therapeutics, Inc.TNGXFY2025
- Vera Therapeutics, Inc.VERAFY2025
Each company listed discloses KYMR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KYMR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IMVT ImmunovantDNLI Denali TherapeuticsPTGX Protagonist TherapeuticsACLX ArcellxDYN Dyne TherapeuticsRNA Avidity BiosciencesIDYA IDEAYA BiosciencesBEAM Beam TherapeuticsIBRX ImmunityBioPCVX VaxcyteBHVN BiohavenVERA Vera TherapeuticsVKTX Viking Therapeutics ApogeeTherapeuticsNUVL Nuvalent
Peer reciprocity
The companies Kymera Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Immunovant (IMVT)247Dyne Therapeutics (DYN)248Avidity Biosciences (RNA)249IDEAYA Biosciences (IDYA)250Vera Therapeutics (VERA)251
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Viking Therapeutics | 2025 | Brian Lian | 672,000 | 17,756,817 | 2,468,016 | 373,000 | 21,269,833 |
| 3 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 4 | Vaxcyte | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 5 | Avidity Biosciences | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 6 | Biohaven | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 7 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 8 | ImmunityBio | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 9 | Nuvalent | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 10 | Ideaya Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 11 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 12 | Vera Therapeutics | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 13 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 14 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 15 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners |
| Avidity Biosciences | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Biohaven | not disclosed | not disclosed | not disclosed | Aon |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Ideaya Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| ImmunityBio | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Immunovant | 110% | not disclosed | No | Compensia |
| Nuvalent | 120% | not disclosed | No | Alpine Rewards |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Vaxcyte | 105% | not disclosed | not disclosed | Pay Governance |
| Vera Therapeutics | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Viking Therapeutics | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-24 | 74,903,687 | 2,462,732 | 26,567 | 96.82% | Passed |
| 2025 | 2025-06-25 | 54,364,880 | 4,531,413 | 11,147 | 92.31% | Passed |
| 2024 | 2024-06-18 | 54,201,734 | 1,599,511 | 6,056 | 97.13% | Passed |
| 2023 | 2023-06-15 | 42,663,379 | 1,519,388 | 5,012 | 96.56% | Passed |
| 2022 | 2022-06-15 | 33,866,486 | 1,793,865 | 3,617,099 | 94.97% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-24 | 96.82%a |
| 2025 | 2025-06-25 | 92.31%b |
| 2024 | 2024-06-18 | 97.13%c |
a. Approved under the standard stated in the filing — “If you abstain from voting on this proposal, your shares will not be counted as "votes cast" with respect to this proposal, and the abstention will have no effect on this proposal.”.
b. Approved under the standard stated in the filing — “If you abstain from voting on this proposal, your shares will not be counted as "votes cast" with respect to this proposal, and the abstention will have no effect on this proposal.”.
c. Approved under the standard stated in the filing — “If you abstain from voting on this proposal, your shares will not be counted as "votes cast" with respect to this proposal, and the abstention will have no effect on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 21 : 1 |
|---|---|
| CEO total compensation | $8,545,609 |
| Median employee compensation | $409,607 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeremy G. Chadwick | Chief Operating Officer | 2026-05-26 | D | 4,500 | $80 | $360,111 | Common | Form 4 ↗ |
| Jeremy G. Chadwick | Chief Operating Officer | 2026-05-27 | D | 600 | 82 | 49,246 | Common | Form 4 ↗ |
| Jeremy G. Chadwick | Chief Operating Officer | 2026-05-27 | D | 3,679 | 82 | 299,850 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-02 | D | 12,653 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-02 | A | 12,653 | 2 | 26,318 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-17 | D | 11,741 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-17 | D | 12,902 | 90 | 1,166,083 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-17 | D | 92,169 | 90 | 8,330,234 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-17 | D | 11,741 | 90 | 1,056,455 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-17 | A | 11,741 | 20 | 234,820 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 4,526 | 92 | 415,713 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 8,809 | 90 | 797,038 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 793 | 92 | 73,083 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 5,672 | 92 | 522,732 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 32,359 | 92 | 2,972,174 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-18 | D | 62,897 | 90 | 5,690,921 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-22 | D | 2,500 | 99 | 247,500 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 1,253 | 102 | 128,407 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 918 | 102 | 93,278 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 3,603 | 99 | 355,184 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 2,247 | 98 | 219,487 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 1,648 | 95 | 156,758 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 286 | 94 | 27,021 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 8,990 | 102 | 921,295 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 6,597 | 102 | 670,321 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 25,976 | 99 | 2,560,714 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 16,084 | 98 | 1,571,085 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 11,783 | 95 | 1,120,799 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 2,035 | 94 | 192,267 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 9,584 | 104 | 1,000,378 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 18,313 | 103 | 1,893,930 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-22 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-22 | A | 2,500 | 21 | 52,625 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 7,319 | 100 | 728,753 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 2,919 | 96 | 280,925 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 56,348 | 100 | 5,644,379 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 52,442 | 100 | 5,221,650 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 20,903 | 96 | 2,011,705 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 1,341 | 104 | 139,974 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 2,560 | 103 | 264,755 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 2,179 | 92 | 200,773 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 7,879 | 100 | 789,239 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-22 | D | 14,921 | 92 | 1,374,821 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-23 | D | 1,235 | 100 | 123,475 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-23 | D | 173 | 100 | 17,297 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-24 | D | 14,490 | 101 | 1,465,519 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-24 | D | 103,688 | 100 | 10,412,349 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Maraganore | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pamela Esposito | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-24 | D | 2,029 | 101 | 205,213 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-24 | D | 14,513 | 100 | 1,457,395 | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gorjan Hrustanovic | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Sandor | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elena Ridloff | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-24 | A | 6,068 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 2,646 | 119 | 313,816 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 3,359 | 118 | 394,683 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,289 | 115 | 147,784 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,437 | 114 | 163,387 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 86 | 111 | 9,528 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 265 | 110 | 29,230 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,399 | 107 | 150,113 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 19,089 | 119 | 2,263,955 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 81,500 | 117 | 9,497,195 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 58,205 | 116 | 6,726,752 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 10,215 | 114 | 1,161,446 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 719 | 112 | 80,449 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,915 | 110 | 211,225 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 14,351 | 109 | 1,561,819 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 46 | 130 | 5,962 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 3,507 | 127 | 446,687 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 223 | 127 | 28,256 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,639 | 125 | 204,236 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,517 | 124 | 187,532 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 5,689 | 121 | 690,531 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 15,660 | 121 | 1,889,536 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 337 | 130 | 43,679 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 2,197 | 129 | 282,732 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 1,609 | 127 | 203,876 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 3,716 | 126 | 467,547 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 10,860 | 124 | 1,342,513 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 4,977 | 123 | 610,529 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 112,299 | 121 | 13,549,997 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 37,179 | 120 | 4,450,698 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 9,994 | 107 | 1,072,356 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 40,774 | 121 | 4,949,148 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 23 | 108 | 2,484 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 24,268 | 118 | 2,851,490 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 614 | 111 | 68,025 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 5,144 | 120 | 615,788 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 11,711 | 125 | 1,459,308 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-25 | D | 2,500 | 119 | 297,500 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-25 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-25 | D | 2,500 | 109 | 272,500 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 11,375 | 117 | 1,325,529 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 8,389 | 116 | 969,517 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 100 | 112 | 11,189 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 9,229 | 115 | 1,058,105 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 159 | 108 | 17,175 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 305 | 129 | 39,250 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 522 | 126 | 65,678 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 698 | 123 | 85,624 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 25,075 | 127 | 3,193,803 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-06-25 | A | 5,000 | 21 | 105,250 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-25 | D | 2,011 | 109 | 218,857 | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-26 | D | 837,914 | 107 | 89,237,841 | Common, indirect | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 1,729 | 119 | 205,163 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 3,069 | 118 | 361,682 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 952 | 116 | 110,137 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 3,896 | 115 | 447,806 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 1,442 | 112 | 160,797 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 1,579 | 110 | 174,464 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 32,402 | 108 | 3,503,952 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 3,958 | 108 | 425,762 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 12,390 | 119 | 1,470,197 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 22,046 | 118 | 2,598,121 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 6,821 | 116 | 789,121 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 27,951 | 115 | 3,212,688 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 555 | 112 | 62,432 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 10,366 | 112 | 1,155,913 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 32,624 | 110 | 3,581,789 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 231,007 | 108 | 24,981,097 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 12,181 | 117 | 1,426,273 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 28,296 | 108 | 3,043,801 | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-26 | D | 51,858 | 107 | 5,522,877 | Common, indirect | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 2,083 | 114 | 237,400 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 4,562 | 110 | 500,862 | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-26 | D | 627,597 | 107 | 66,839,081 | Common, indirect | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 1,701 | 117 | 199,170 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 78 | 112 | 8,774 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 14,913 | 114 | 1,699,635 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-26 | D | 11,277 | 110 | 1,245,996 | Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-26 | D | 113,289 | 107 | 12,065,279 | Common, indirect | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,239 | 110 | 135,980 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 157 | 111 | 17,458 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 848 | 106 | 89,701 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 19,093 | 108 | 2,057,462 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 907 | 111 | 100,858 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 7,833 | 110 | 859,672 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 10,658 | 108 | 1,154,048 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,078 | 111 | 119,302 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,104 | 110 | 121,164 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 2,698 | 108 | 290,736 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 2,133 | 107 | 227,442 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 5,471 | 106 | 578,722 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 934 | 111 | 103,861 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 14,798 | 107 | 1,577,911 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 2,318 | 107 | 247,168 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 3,024 | 108 | 325,866 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 14,613 | 107 | 1,558,184 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,688 | 108 | 182,777 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,498 | 108 | 162,203 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 770 | 106 | 81,451 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 7,723 | 111 | 854,704 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 7,968 | 110 | 874,488 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 10,848 | 108 | 1,174,621 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 19,419 | 108 | 2,092,591 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 5,549 | 106 | 586,973 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 1,199 | 111 | 132,693 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 7,602 | 111 | 841,313 | Common | Form 4 ↗ |
| Bruce Booth | Director | 2026-06-29 | D | 130 | 111 | 14,456 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 51,375 | 115 | 5,896,288 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 1,100 | 113 | 124,067 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 1,700 | 112 | 189,664 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 1,500 | 111 | 165,810 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 6,153 | 117 | 719,862 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 7,971 | 116 | 923,178 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 4,110 | 114 | 469,311 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 61,378 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | A | 61,378 | 5 | 327,145 | Common | Form 4 ↗ |
| Bruce Jacobs | Chief Financial Officer | 2026-06-30 | D | 3,200 | 118 | 376,649 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 24,105 | 115 | 2,771,002 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 44,050 | 116 | 5,096,070 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | A | 80,000 | 2 | 166,400 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 80,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 3,336 | 117 | 388,841 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 1,883 | 113 | 212,411 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-01 | D | 6,626 | 114 | 755,204 | Common | Form 4 ↗ |
| Noah Goodman | Chief Business Officer | 2026-07-01 | D | 3,389 | 114 | 387,329 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-07 | D | 4,441 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-07 | A | 50,000 | 2 | 104,000 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-07 | D | 45,559 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-07-07 | D | 50,000 | 119 | 5,950,000 | Common | Form 4 ↗ |
| Terence Rooney | Chief Medical Officer | 2026-07-27 | A | 38,000 | 0 | 0 | Common | Form 4 ↗ |
| Terence Rooney | Chief Medical Officer | 2026-07-27 | A | 76,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Adams | Chief Legal Officer | 2026-09-04 | D | 2,137 | 118 | 251,247 | Common | Form 4 ↗ |
| Brian Adams | Chief Legal Officer | 2026-09-04 | D | 3,025 | 117 | 353,350 | Common | Form 4 ↗ |
| Brian Adams | Chief Legal Officer | 2026-09-04 | D | 1,209 | 116 | 139,700 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 8,230 | 115 | 949,742 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 7,601 | 114 | 869,782 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 4,876 | 113 | 552,158 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 5,506 | 112 | 618,985 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | A | 30,000 | 2 | 62,400 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 3,525 | 111 | 392,826 | Common | Form 4 ↗ |
| Nello Mainolfi | Director | 2026-10-01 | D | 262 | 116 | 30,423 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (251 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nello Mainolfi. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table” · page 36. As printed: 8,545,609. View filing ↗
- Section 01, Brian Adams. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 6,071,041. View filing ↗
- Section 01, Noah Goodman. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 3,172,068. View filing ↗
- Section 01, Jared Gollob. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 2,914,330. View filing ↗
- Section 01, Bruce Jacobs. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 2,903,236. View filing ↗
- Section 03, Nello Mainolfi OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, MBA OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, MBA RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jared Gollob RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Adams RSU. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Bruce Jacobs RSU. DEF 14A, filed 2026-04-29. Section “THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF KYMERA THERAPEUTICS, INC. &” · grants of plan-based awards table. View filing ↗
- Section 03, Jared Gollob OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Bruce Jacobs OPTION. DEF 14A, filed 2026-04-29. Section “THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF KYMERA THERAPEUTICS, INC. &” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Adams OPTION. DEF 14A, filed 2026-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-29. Section “CEO Pay Ratio”. As printed: 21 : 1. View filing ↗
- Section 08, Bruce Booth. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 642,996. View filing ↗
- Section 08, Jeffrey Albers. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 637,996. View filing ↗
- Section 08, Felix J. Baker. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 636,871. View filing ↗
- Section 08, Elena Ridloff. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 632,996. View filing ↗
- Section 08, Pamela Esposito. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 630,579. View filing ↗
- Section 08, John Maraganore. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 620,496. View filing ↗
- Section 08, Gorjan Hrustanovic Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 617,996. View filing ↗
- Section 08, Victor Sandor. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 612,996. View filing ↗
- Section 08, Leigh Morgan. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 27,792. View filing ↗
- Section 08, Nello Mainolfi. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jeremy G. Chadwick 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy G. Chadwick 2026-05-27. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy G. Chadwick 2026-05-27. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Maraganore 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pamela Esposito 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gorjan Hrustanovic 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Sandor 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elena Ridloff 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Booth 2026-06-29. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce Jacobs 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Goodman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-07. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-07. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-07. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-07-07. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terence Rooney 2026-07-27. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terence Rooney 2026-07-27. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Adams 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Adams 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Adams 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nello Mainolfi 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-24. Item 5.07 · say-on-pay result. As reported: 96.82% (votes for as printed: 74,903,687). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-27. Item 5.07 · say-on-pay result. As reported: 92.31% (votes for as printed: 54,364,880). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-20. Item 5.07 · say-on-pay result. As reported: 97.13% (votes for as printed: 54,201,734). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 476,750 + equity 0 + all other 0 = 476,750, summed across the director compensation table rows.
- Arcellx, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. View filing ↗
- Viking Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Viking Therapeutics's own proxy. As printed: 21,269,833. View filing ↗
- Immunovant, Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. View filing ↗
- Vaxcyte, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. View filing ↗
- Avidity Biosciences, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. View filing ↗
- Biohaven, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven's own proxy. As printed: 13,500,438. View filing ↗
- Protagonist Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
- ImmunityBio, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio's own proxy. As printed: 12,716,953. View filing ↗
- Nuvalent, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. View filing ↗
- Ideaya Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences's own proxy. As printed: 9,512,640. View filing ↗
- Kymera Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
- Vera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics's own proxy. As printed: 6,986,410. View filing ↗
- Beam Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Dyne Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. View filing ↗
- Section 10a, Immunovant reciprocity. DEF 14A. Immunovant names Kymera Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Dyne Therapeutics reciprocity. DEF 14A. Dyne Therapeutics names Kymera Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Avidity Biosciences reciprocity. DEF 14A. Avidity Biosciences names Kymera Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, IDEAYA Biosciences reciprocity. DEF 14A. IDEAYA Biosciences names Kymera Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Vera Therapeutics reciprocity. DEF 14A. Vera Therapeutics names Kymera Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗